BlackRock Fund Advisors’s Crescent Biopharma CBIO Stock Holding History

BlackRock Fund Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.43M	Buy	3,978 +761	+24%	+$475K	﹤0.01%	3127
2016 Q3	$2.3M	Buy	3,217 +518	+19%	+$396K	﹤0.01%	3129
2016 Q2	$1.96M	Buy	2,699 +2,454	+1,002%	+$1.69M	﹤0.01%	3195
2016 Q1	$146K	Sell	245 -19	-7%	-$9.74K	﹤0.01%	3566
2015 Q4	$151K	Buy	264 +10	+4%	+$6.63K	﹤0.01%	3627
2015 Q3	$142K	Sell	254 -7	-3%	-$5.05K	﹤0.01%	3602
2015 Q2	$207K	Buy	261 +32	+14%	+$26.5K	﹤0.01%	3521
2015 Q1	$191K	Sell	229 -16	-7%	-$12.4K	﹤0.01%	3501
2014 Q4	$176K	Buy	245 +18	+8%	+$14.1K	﹤0.01%	3517
2014 Q3	$158K	Sell	227 -17	-7%	-$13.8K	﹤0.01%	3548
2014 Q2	$206K	Sell	244 -1,970	-89%	-$1.96M	﹤0.01%	3481
2014 Q1	$3.62M	Buy	+2,214	New	+$2.68M	﹤0.01%	2985

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

BlackRock Fund Advisors's CBIO Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Crescent Biopharma (CBIO) stake by 24% in Q4 2016, buying an estimated $475K and bringing the position to 3,978 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

BlackRock Fund Advisors first reported a position in CBIO in Q1 2014 and has held it in 12 quarters since. The position peaked at $3.62M in Q1 2014. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

BlackRock Fund Advisors held 3,978 shares of Crescent Biopharma worth $2.43M as of Q4 2016.
BlackRock Fund Advisors bought 761 Crescent Biopharma shares in Q4 2016, an estimated $475K.
Crescent Biopharma made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3127 holding.
BlackRock Fund Advisors first reported a position in Crescent Biopharma in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Crescent Biopharma position peaked at $3.62M in Q1 2014.
50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.